Clinical Trial

Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is an open-label extension study to evaluate the long-term safety of relacorilant in patients with endogenous Cushing syndrome who successfully completed participation in a Corcept-sponsored study of relacorilant and may benefit from continuing treatment.
Protocol Amendment History 44 amendments
This ClinicalTrials.gov record has been amended 44 times since 2018-07-19; most recent amendment 2026-04-16.
Status change: Enrolling by Invitation → Active, Not Recruiting 2024-12-04
Status change: Recruiting → Enrolling by Invitation 2020-03-13
Trial Details
NCT Number NCT03604198
Lead Sponsor Corcept Therapeutics
Conditions Cushing Syndrome
Enrollment 125 participants
Start Date 2018-05-07
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-08-13